The Molecular Tumor Board

The implementation of a molecular tumour board (MTB) offers a further opportunity to increase the chances of targeted and personalized cancer treatment for patients in addition to a tumour conference. Through gene sequencing (panel sequencing) and other molecular examinations, it is possible to identify genetic changes in a tumor disease. Some of these genetic changes may point to new therapeutic target structures and consequently open up new treatment options in cancer therapy.

The MTB is downstream of the organ tumor conference and can be considered for selected patients. The aim is to develop an individual treatment concept for individual cancer patients with rare or advanced malignant diseases for whom a guideline-based treatment option is not (or no longer) available or for whom previous treatments have been unsuccessful.

The Molecular Tumour Board (MTB) is the central instrument in personalized medicine. At the beginning of 2022, the MTB at the Hanover site was transferred to the Centre for Personalized Medicine (ZPM) .


Prerequisite for registration

Registration and discussion of patients in the Molecular Tumor Board (MTB) if the following conditions are met:

  • Advanced tumor disease with failure of guideline-compliant standard therapy or no prospect of success with the still available guideline-compliant standard therapy
  • Rare/aggressive oncological diseases or those with an unusual clinical course may be presented at an earlier stage
  • Recommendation for molecular genetic diagnostics with subsequent presentation in the molecular tumor board by organ tumor conference
  • Physical and mental condition and life expectancy justify continuation of treatment

Colleagues outside the MHH can also present their patients to our Molecular Tumor Board in order to receive a possible alternative treatment recommendation based on molecular analyses.

Moleculardiagnostics are already available: Register your patient directly via the registration form with the findings for the Molecular Tumor Board.

Molecular diagnosticsare not yet available: If no molecular pathological diagnostics are available, you have the option of having these carried out by the MHH pathology department. To do this, send the sample material to the pathology department and order the corresponding analysis.

You also have the option of a combined registration of analysis in the pathology department with subsequent presentation to the molecular tumor board. To do this, you send a completed registration form to the pathology department together with the order for the analysis and the presentation at the molecular tumor board is then initiated internally.

Ordering molecular pathological diagnostics at the MHH

Model project genome sequencing

The MHH is a service provider in the genome sequencing pilot project in accordance with Section 64e SGB V for the area of oncological diseases. The model project is intended to help integrate genetic tests for the diagnosis and treatment of rare and cancer-related diseases into healthcare. As a result, diseases can be diagnosed earlier and more precisely and individual, better coordinated treatments can be made possible.

Here you can find further information on the pilot project (for MHH-internal patient registrations, only accessible internally at MHH).


Contact

mtb-ccc@mh-hannover.de
0511-532-19341
Fax: 0511-532-161170

Your contact persons

Portrait of Anna Saborowski
PD Dr. med. Anna Saborowski
Head of the Center for Personalized Medicine at the CCC Hannover
    • saborowski.anna@mh-hannover.de
      • Deputy Member of the Board of the CCC Hannover
      • Senior Physician in the Clinical Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology